First specialist adult ADHD medication approved for the UK

Adults with attention deficit hyperactivity disorder (ADHD) can now be offered a treatment specifically licensed for their condition after the Medicines & Healthcare Products Regulatory Agency (MHRA) authorised the use of Strattera (atomoxetine). About 1.7 million adults are estimated to have ADHD in the UK. ADHD can have a serious impact on social and functional performance in adults, affecting family and social relationships, work and psychological health. Continuing treatment from childhood Until now, adults with ADHD could only receive medication if they were continuing treatment from childhood. Strattera, manufactured by pharmaceutical company Lilly, is the first treatment to receive a